Status:
COMPLETED
A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose this study is to evaluate the safety and toleration of PF-03049423 following multiple dose administration as an oral solution to healthy young adult volunteers and healthy elderly voluntee...
Detailed Description
The purpose of the investigation is to evaluate the safety and tolerability of an investigational new drug, PF-03049423, when dosed for two weeks in both healthy younger and healthy older subjects.
Eligibility Criteria
Inclusion
- Healthy persons, male or female.
- For the healthy young adult cohort, subjects must be 18 to 50 years old, inclusive.
- For the healthy elderly adult cohort, subjects must be 51 to 99 years old, inclusive.
- Body Mass Index (BMI) of 18 to 35; and a total body weight \>50 kg (110 lbs)
Exclusion
- Subjects with clinically significant medical conditions.
- Women of non-child bearing potential.
- Subjects with a known medical history of hearing loss/disability or nonarteritic ischemic optic neuropathy.
- A positive urine drug screen.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01161069
Start Date
August 1 2009
End Date
December 1 2009
Last Update
August 9 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, 1070